Growth factor based therapies and intestinal disease: Is glucagon-like peptide-2 the new way forward?

被引：37

作者：

Yazbeck, Roger ^{[1
,2
]}

Howarth, Gordon S. ^{[1
,2
,3
]}

Abbott, Catherine A. ^{[1
]}

机构：

[1] Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA 5001, Australia

[2] Womens & Childrens Hosp, Ctr Paediat & Adolescent Gastroenterol, Adelaide, SA, Australia

[3] Univ Adelaide, Sch Agr Food & Wine, Discipline Agr & Anim Sci, Adelaide, SA 5005, Australia

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2009年 / 20卷 / 02期

关键词：

Dipeptidyl peptidase-IV; Glucagon-like peptide-2; Inflammatory bowel disease; Animal model; INFLAMMATORY-BOWEL-DISEASE; GASTRIC-ACID-SECRETION; FACTOR-I; EXPERIMENTAL COLITIS; GLP-2; RECEPTOR; EPITHELIAL PROLIFERATION; PARENTERAL-NUTRITION; GENE-EXPRESSION; CELL-SURVIVAL; UP-REGULATION;

D O I：

10.1016/j.cytogfr.2009.02.008

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Inflammatory bowel disease (IBD) is a chronic, debilitating disease associated with severe damage to the intestinal mucosa. Glucagon-like peptide-2 (GLP-2) is a potent and specific gastrointestinal growth factor that is demonstrating therapeutic potential for the prevention or treatment of an expanding number of intestinal diseases, including short bowel syndrome (SBS), small bowel enteritis and IBD. The biological activity of GLP-2 is limited due to proteolytic inactivation by the protease dipeptidyl peptidase (DP)IV. Inhibitors of DPIV activity may represent a novel strategy to prolong the growth promoting actions of GLP-2. This review outlines evidence for the clinical application of GLP-2, its degradation resistant analogue, Teduglutide, and novel DPIV inhibitors in efficacy studies utilizing pre-clinical models of intestinal damage, in particular IBD. (C) 2009 Published by Elsevier Ltd.

引用

页码：175 / 184

页数：10

共 108 条

[1]

Alavi K, 2000, J PEDIATR SURG, V35, P847, DOI 10.1053/jpsu.2000.6861

[2] Biologic therapy for inflammatory bowel disease [J].

Ardizzone, S ;

Porro, GB .

DRUGS, 2005, 65 (16) :2253-2286

[3] Inflammatory bowel disease: new insights into pathogenesis and treatment [J].

Ardizzone, S ;

Porro, GB .

JOURNAL OF INTERNAL MEDICINE, 2002, 252 (06) :475-496

[4] Glucagonlike peptide-2 analogue: A possible new approach in the management of inflammatory bowel disease [J].

Arthur, GL ;

Schwartz, MZ ;

Kuenzler, KA ;

Birbe, R .

JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (03) :448-452

[5]

Awada A, 2005, NEW ENGL J MED, V352, P1264

[6] Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets [J].

Bartholome, AL ;

Albin, DM ;

Baker, DH ;

Holst, JJ ;

Tappenden, KA .

JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2004, 28 (04) :210-222

[7] Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse [J].

Benjamin, MA ;

McKay, DM ;

Yang, PC ;

Cameron, H ;

Perdue, MH .

GUT, 2000, 47 (01) :112-119

[8] Modulation of specific intestinal epithelial progenitors by enteric neurons [J].

Bjerknes, M ;

Cheng, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (22) :12497-12502

[9] Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage [J].

Booth, C ;

Booth, D ;

Williamson, S ;

Demchyshyn, LL ;

Potten, CS .

CELL PROLIFERATION, 2004, 37 (06) :385-400

[10] Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis [J].

Boushey, RP ;

Yusta, B ;

Drucker, DJ .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 277 (05) :E937-E947

← 1 2 3 4 5 6 7 8 9 10 →